NasdaqGS:CNTABiotechs
How Elevating Orexin Program Leader to CEO Could Reshape Centessa Pharmaceuticals' (CNTA) Strategic Focus
On December 11, 2025, Centessa Pharmaceuticals announced that Mario Alberto Accardi PhD will become CEO and join the Board on January 1, 2026, while current CEO Saurabh Saha MD PhD will step down and move into an advisory role.
This leadership transition elevates the head of Centessa’s orexin program, now the company’s primary focus, potentially sharpening its execution around orexin-based therapies.
We’ll now examine how putting the orexin program leader in the CEO role may influence...